Metronomic Capecitabine Plus Aromatase Inhibitor Boosts Survival in HR+ Breast Cancer
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either metronomic capecitabine plus AI or AI alone.